secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aridis Pharmaceuticals, Inc. (—)
CIK:        0001614067
Form:       8-K
Filed at:   2023-04-21T23:59:59+00:00
Accession:  0001493152-23-013232
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aridis receives additional Nasdaq delisting notice for late 10-K; also non-compliant on board composition
--------------------------------------------------------------------------------

- Nasdaq issued second delisting basis for failure to file 2022 Form 10-K; hearing already set for May 4, 2023.
- Company has until April 26, 2023 to request stay of suspension pending hearing; plans to do so.
- Separate notice: board independence and audit committee rules violated due to Craig Gibbs resignation on March 27, 2023.
- Cure period for board independence runs until next annual meeting or March 27, 2024, whichever earlier.
- Company already facing delisting for failing to meet $35M minimum market value of listed securities requirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1614067/000149315223013232/0001493152-23-013232-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1614067/000149315223013232/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-013232

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer